Auro Laboratories Reports Strong Q3FY26 Results with 206% Revenue Growth
Auro Laboratories Limited reported exceptional Q3FY26 results with revenue from operations surging 206% to ₹939.30 lakhs and net profit jumping to ₹195.18 lakhs from ₹5.10 lakhs in Q3FY25. The nine-month performance also remained strong with revenue growing 76% to ₹2,090.56 lakhs and net profit increasing 129% to ₹266.18 lakhs. The Board approved these results on February 5, 2026, following audit committee review and statutory auditor's limited review.
*this image is generated using AI for illustrative purposes only.
Auro Laboratories Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, demonstrating exceptional growth across all key performance indicators. The pharmaceutical company's Board of Directors approved these results during their meeting held on February 5, 2026.
Outstanding Quarterly Performance
The company delivered remarkable financial performance in Q3FY26, with revenue from operations reaching ₹939.30 lakhs compared to ₹306.47 lakhs in Q3FY25, marking an impressive 206% year-on-year growth. This substantial increase reflects the company's strengthened market position and operational efficiency.
| Financial Metric: | Q3FY26 | Q3FY25 | Growth (%) |
|---|---|---|---|
| Revenue from Operations: | ₹939.30 lakhs | ₹306.47 lakhs | +206% |
| Total Income: | ₹957.03 lakhs | ₹319.56 lakhs | +199% |
| Net Profit: | ₹195.18 lakhs | ₹5.10 lakhs | +3,727% |
| Basic EPS: | ₹3.13 | ₹0.08 | +3,813% |
Profitability Surge
Net profit for Q3FY26 soared to ₹195.18 lakhs from ₹5.10 lakhs in the corresponding quarter of the previous year, representing an extraordinary growth of 3,727%. The profit before tax stood at ₹173.84 lakhs compared to ₹6.81 lakhs in Q3FY25. Basic earnings per share improved significantly to ₹3.13 from ₹0.08 in the previous year quarter.
Nine-Month Performance Highlights
For the nine-month period ended December 31, 2025, Auro Laboratories maintained its strong momentum with revenue from operations of ₹2,090.56 lakhs against ₹1,185.82 lakhs in the corresponding period of FY25. Net profit for the nine-month period reached ₹266.18 lakhs compared to ₹116.17 lakhs in the previous year.
| Nine-Month Metrics: | FY26 (9M) | FY25 (9M) | Growth (%) |
|---|---|---|---|
| Revenue from Operations: | ₹2,090.56 lakhs | ₹1,185.82 lakhs | +76% |
| Total Income: | ₹2,225.32 lakhs | ₹1,252.85 lakhs | +78% |
| Net Profit: | ₹266.18 lakhs | ₹116.17 lakhs | +129% |
| Basic EPS: | ₹4.11 | ₹1.86 | +121% |
Operational Efficiency and Cost Management
The company demonstrated improved operational efficiency with total expenses of ₹783.16 lakhs in Q3FY26 compared to ₹312.75 lakhs in Q3FY25. Notable changes in inventory management contributed positively, with changes in inventories showing a favorable impact of ₹199.74 lakhs compared to an adverse impact of ₹110.38 lakhs in the previous year quarter.
Comprehensive Income and Capital Structure
Total comprehensive income for Q3FY26 stood at ₹179.95 lakhs compared to ₹8.88 lakhs in Q3FY25. The company maintains a stable capital structure with paid-up equity share capital of ₹623.25 lakhs, consisting of equity shares with a face value of ₹10 each. Other equity as of March 31, 2025, was ₹3,673.56 lakhs.
Regulatory Compliance and Audit
The unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS 34) and reviewed by the Audit Committee before Board approval. B.L. Dasharda & Associates, the company's statutory auditors, conducted a limited review of these results as per Regulation 33 of SEBI (LODR) Regulations, 2015. The company operates in a single segment of pharmaceuticals and has made appropriate provisions for gratuity in accordance with new Labour Codes implemented from November 21, 2025.
Historical Stock Returns for Auro Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.35% | +21.90% | +8.99% | -0.80% | +13.32% | +166.06% |
17
